Tuam Tshoj Sacubitril Hemicalcium manufacturers thiab lwm tus neeg

Sacubitril Hemicalcium hmoov

Lus piav qhia luv luv:

API lub npe	Qhov taw qhia	Specification	US DMF	EU DMF	CEP
Sacubitril Hemicalcium hmoov		Hauv tsev

Xa email rau peb

Product Detail

Khoom cim npe

KHOOM PLIG

沙库比曲半钙盐	Sacubitril Hemicalcium hmoov	1369773-39-6	Hauv tsev
沙库比曲钠盐		149690-05-1, ib	Hauv tsev
LCZ-4		1426129-50-1	Hauv tsev
LCZ-7		1012341-48-8	Hauv tsev
LCZ-8		1012341-50-2	Hauv tsev
LCZ-9		149690-12-0	Hauv tsev

Keeb kwm

AHU-377 hemicalcium ntsev yog hemicalcium ntsev daim ntawv ntawm AHU-377. Nws yog ib qho inhibitor ntawm neprilysin nrog IC50 tus nqi ntawm 5 nM [1].

AHU-377 thiab angiotensin II AT1 receptor antagonist valsartan sau LCZ696 hauv 1: 1 molar ratio. LCZ696 yog angiotensin receptor neprilysin inhibitor. Nws tuaj yeem txo cov ntshav siab thiab tej zaum yuav yog ib qho tshuaj tshiab rau kev kho mob plawv. AHU-377 yog ib qho tshuaj tiv thaiv, nws tuaj yeem hloov pauv los ntawm enzymatic cleavage ntawm ethyl ester rau hauv daim ntawv nquag LBQ657. Nws tau tshaj tawm tias AHU-377 (30 thiab 100 mg / kg, PO) tuaj yeem ua rau cov nyhuv antihypertensive nyob rau hauv cov koob tshuaj raws li DAHI-SS nas. Tab sis nyob rau hauv DOCA- ntsev hypertensive nas, nws qhia tau hais tias tsis muaj zog txo [2, 3].

Cov ntaub ntawv:
[1] Ksander GM, Ghai RD, deJesus R, Diefenbacher CG, Yuan A, Berry C, Sakane Y, Trapani A. Dicarboxylic acid dipeptide neutral endopeptidase inhibitors. J Med Chem. 1995 Tsib Hlis 12; 38(10):1689-700.
[2] Voors AA, Dorhout B, van der Meer P. Lub luag haujlwm ntawm valsartan + AHU377 (LCZ696) hauv kev kho mob plawv. Expert Opin Investig Drugs. 2013 Aug; 22(8:1041-7.
[3] Laxminarayan G Hegde, Cecile Yu, Cheruvu Madhavi et al. Kev sib piv kev ua tau zoo ntawm AHU-377, ib qho muaj zog neprilysin inhibitor, hauv ob lub qauv nas ntawm ntim-nyob ntawm qhov kub siab. BMC Pharmacology 2011, 11(Suppl 1): P33.